Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib plus RFA for recurrent HCC
NCT03097848Unknown
- Sponsor
- Southwest Health System
- Start
- May 2017
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of sorafenib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Southwest Health System. Primary endpoint: Disease free survival at 1 year. Status: unknown.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03097848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03097848.